Oligometastatic carcinoma prostate – An overview of the last decade

INTRODUCTION: Oligometastatic prostate cancer (OMPC) has gained profound interest lately due to its different tumor biology and our ability to use multimodality therapy for cure or prolonged survival. Selecting the appropriate patient for treatment has become the aim of treating urologists, medical oncologists, and radiation oncologists. Through this review, we try to highlight the management of OMPC in light of recent literature. METHODS: Literature search was performed on Pubmed, Scopus and Embase using keywords “Oligometastatic”, “ Prostate Cancer” using operators such as “And” & “Or”. Relevant articles were screened and all the latest articles on this emerging entity were included in this review. RESULTS: All trials relevant to oligometastatic prostate cancer defining the role of surgery, radiotherapy and systemic therapy were included and appropriate inferences were drawn. Relevant studies were compiled in tabular form for this article. CONCLUSION: The current standard of care of management for OMPC remains systemic therapy on the lines of hormone-sensitive metastatic prostate cancer. The evolving role of surgery, and radiotherapy along with systemic therapy is highlighted in this article.